Comparing Dexcom G7 Continuous Glucose Monitoring to Standard Point of Care Testing for Managing Hospitalized Adults with Type 1 Diabetes

What this Trial Is About

This research aims to compare two methods of glucose monitoring for hospitalized adults with poorly controlled Type 1 Diabetes Mellitus. It evaluates whether the Dexcom G7 Continuous Glucose Monitoring CGM system offers better control of blood sugar levels and reduces low blood sugar episodes compared to the standard Point of Care POC Blood Glucose Testing. The study addresses a significant gap in understanding the best glucose monitoring method for hospitalized patients with this condition. Participants will be randomly assigned to one of two groups. One group will receive standard care with POC glucose testing before meals and at bedtime, with insulin adjusted based on these readings, while wearing a blinded CGM device that does not display data during hospitalization for up to 10 days. The other group will wear the Dexcom G7 real-time CGM device for up to 10 days, with insulin therapy adjusted using detailed CGM data including average glucose levels and hypoglycemic episodes. Both groups start after severe hyperglycemia resolves. Throughout the study, researchers will monitor blood sugar control and track hypoglycemic events up to 10 days or until the hospital stay ends. They will assess various outcomes such as time spent in target glucose range, blood sugar variability, and hospital complications. Data collection involves glucose readings uploaded to medical records, with insulin adjustments guided by either POC or CGM results. The study includes follow-up during hospitalization and post-discharge periods.

A Study Comparing Dexcom Continuous Glucose Monitoring to Point of Care Glucose Testing for the Management of Hospital and Post-Discharge Subjects With Type 1 Diabetes